CHARLES B. GOODWIN, District Judge.
Now before the Court is the Motion for Partial Judgment on the Pleadings filed pursuant to Federal Rule of Civil Procedure 12(c) by Defendants SandRidge Energy, Inc. ("SandRidge"),
SandRidge explored, developed, and produced natural gas and oil reserves in, among other locations, the Mississippian Formation, "a geological formation located in northern Oklahoma and south-central Kansas." Consol. Am. Compl. ¶ 87. "[T]o finance increased capital expenditures planned for 2011, SandRidge decided to `monetize' certain of its existing oil and gas assets in [n]orthern Oklahoma by selling interests in those assets to the public via a royalty trust." Id. ¶ 4. To this end, SandRidge created Trust I and conveyed to it royalty interests consisting of a share of SandRidge's revenue from (a) existing horizontal oil and gas wells in five Oklahoma counties, collectively referred to as the "Trust I Area of Mutual Interest" ("Trust I AMI"), and (b) specific horizontal oil and gas wells to be drilled in the Trust I AMI. See id. To pay for these royalty interests, Trust I committed to sell common units to investors in an initial public offering ("Trust I IPO") and transfer the net proceeds of that sale to SandRidge. Id. ¶ 5.
SandRidge thereafter decided to raise additional funds to finance its capital expenditures and in December 2011 formed the SandRidge Mississippian Trust II ("Trust II"). Id. ¶ 19. SandRidge conveyed to Trust II royalty interests consisting of a share of SandRidge's revenue from (a) existing horizontal wells in nine counties in Oklahoma and Kansas, collectively referred to as the "Trust II Area of Mutual Interest" ("Trust II AMI"), and (b) certain horizontal oil and gas wells to be drilled in the Trust II AMI. Id. As with Trust I, to compensate SandRidge for these royalty interests Trust II committed to sell common units in an initial public offering ("Trust II IPO") and transfer those proceeds to SandRidge. Id. ¶ 20.
In November 2012, SandRidge made certain statements that concerned the performance of oil and gas wells in the Mississippian Formation. In a press release dated November 8, 2012, SandRidge "reported a `net loss applicable to common stockholders of $184 million, or $0.39 per diluted share, for third quarter 2012 compared to net income available to common stockholders of $561 million, or $1.16 per diluted share, in third quarter 2011.'" Id. ¶ 227.
The next day, "before markets opened, SandRidge held a conference call for analysts and investors to discuss the financial results and other information in the . . . [p]ress [r]elease." Id. ¶ 228. During that earnings call, Defendant Ward, who was SandRidge's founder and then chief executive officer and chairman of SandRidge's Board of Directors, "disclosed that . . . SandRidge's wells in the Mississippian Formation consisted of far more gas and far [fewer] oil deposits than the market had previously been led to believe." Id. In response to an analyst's "concern over the drop in oil production in the Mississippian Formation," "Defendant Ward conceded that wells in the Mississippian Formation . . . were producing less oil." Id. ¶ 230. On that same call, Defendant Grubb, then SandRidge's president and president and chief operating officer of Trust I and Trust II, further disclosed:
Id. ¶ 229.
Following these disclosures, the prices of SandRidge common stock and Mississippian Trust units dropped. SandRidge's common stock declined from a close of $6.10 per share on November 8, 2012, to a close of $5.51 per share on November 9, 2012. See Decl. of Mark P. Gimbel, Ex. 1 (Doc. No. 216-1) at 11, ¶ 12.
On December 5, 2012, a complaint was filed in this Court on behalf of a putative class of investors in SandRidge common stock, asserting claims against SandRidge, Ward, Grubb, and Bennett (who was executive vice president of SandRidge and chief financial officer of both SandRidge and the two Trusts). See Glitz v. SandRidge Energy, Inc., Case No. CIV-12-1341 (W.D. Okla.). Initially, no claims were asserted on behalf of Trust I or Trust II investors, and neither Trust I nor Trust II was a named defendant.
The Complaint alleged that SandRidge, together with its officers and directors, had violated federal securities laws by "disseminati[ng] . . . false and misleading statements concerning . . . [SandRidge's] business and operational status and FY 2012 financial expectations." Glitz, Compl. (Doc. No. 1) ¶ 1. The Complaint contended that "the truth" about defendants' conduct had "beg[un] to be revealed" on November 8, 2012, through a "publicly issued . . . letter" written by "D[i]nakar Singh, CEO of . . . TPG-Axon, which then owned 4.5% of SandRidge's stock." Id. ¶ 52 (emphasis and capitalization omitted). This letter discussed "SandRidge's `disastrous performance' and over 76% decline in its stock price." Id. To this end, the Complaint also cited a November 8, 2012 press release, in which "Defendants [had] reported a loss of $184 million, or 39 cents per share, in the 3Q 2012, compared with a profit of $561 million, or $1.16 per share, in the 3Q 2011." Id. ¶ 54 (emphasis omitted). And it cited a November 9, 2012 conference call, during which "Defendant Ward [had] acknowledged that SandRidge had been overstating the value of its Mississippian assets . . ., disclosing that in reality, [SandRidge's] Mississippian formation assets consisted of far more low-margin natural gas deposits and far fewer highmargin oil deposits than the market had previously been led to believe." Id.
The Complaint also alleged that the defendants had made misstatements and omissions about "the extent and value of [SandRidge's] oil reserves" so that SandRidge could "monetize its interests in the Mississippian formation assets." Id. ¶ 66. These misstatements and omissions, said the plaintiffs, had "[a]rtificially inflat[ed] and manipulat[ed] SandRidge's stock price," and when they "became apparent to the market on November 8, 2012, SandRidge's stock price fell precipitously." Id. ¶ 67.
Glitz was eventually consolidated with Carbone v. SandRidge Energy, Inc., Case No. CIV-13-19, also pending in the Western District of Oklahoma. See Glitz, Order of Mar. 6, 2013 (Doc. No. 60) (West, J.). Laborers Pension Trust Fund for Northern Nevada, Construction Laborers Pension Trust of Greater St. Louis, Vladimir Galkin, and Angela Galkin, purchasers of SandRidge common stock, were appointed Lead Plaintiffs in the restyled consolidated action. See id. at 2, 4. In July 2013, they amended their complaint. See In re SandRidge Energy, Inc. Securities Litigation, Case No. CIV-12-1341-G ("SandRidge"), Doc. Nos. 67, 73, 75.
Named as additional plaintiffs in that pleading were Judith Greenberg, Charles Blackburn, and Ted Odell, who sought to assert claims on behalf of a putative class of purchasers of Trust I and Trust II Units. See SandRidge Compl. (Doc. No. 75) ¶¶ 1, 23-25. `These Trust I and II Unitholders likewise alleged that Defendants' alleged misrepresentations and omissions about wells in the Mississippian Formation had artificially inflated the price of Trust I and Trust II Units. They further alleged that, "[a]s a direct result of Defendants' disclosures" on November 8 and 9, 2012, and "a materialization of the undisclosed risk of investing in . . . the SandRidge Trusts," the price of Trust I and Trust II Units "fell precipitously." See id. ¶¶ 329-331, 361.
On May 11, 2015, the Court dismissed the claims brought by Greenberg, Blackburn, and Odell without prejudice for failure to comply with certain requirements of the Private Securities Litigation Reform Act of 1995 ("PSLRA"), 15 U.S.C. § 78u-4. See SandRidge, Order of May 11, 2015 (Doc. No. 180) (West, J.).
On June 9, 2015, immediately after the dismissal of the claims of Greenberg, Blackburn, and Odell in SandRidge, Lanier brought the instant action. See Compl. (Doc. No. 1). A consolidated amended complaint followed on November 11, 2016. See Am. Compl. (Doc. No. 78).
Relief was sought under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act"), as amended by the PSLRA, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, promulgated thereunder. See 17 C.F.R. § 240.10b-5. Lead Plaintiffs also sought to hold certain defendants liable under sections 11, 12(a)(2), and 15 of the Securities Act of 1933 ("Securities Act"), 15 U.S.C. §§ 77k, 77l(a)(2) and 77o.
The Exchange Act and Rule 10b-5 claims were asserted against Trust I and nominal Defendant SandRidge as well as against Defendants Ward, Bennett, and Grubb. The Securities Act claims were asserted against both Trust I and Trust II, SandRidge, Ward, Bennett, and Grubb. Also named as Defendants were Randall D. Cooley, who served as SandRidge's senior vice president-accounting, members of SandRidge's Board of Directors (Jim J. Brewer, Everett R. Dobson, William A. Gilliland, Daniel W. Jordan, Roy T. Oliver, Jr., and Jeffrey S. Serota), and certain entities that had underwritten the Trusts' offerings and/or had helped draft and disseminate prospectuses for the two offerings.
On August 30, 2017, the Court, without objection, dismissed Lead Plaintiffs' Securities Act claims. See Order of Aug. 30, 2017 (Doc. No. 129) (Miles-LaGrange, J.). Judgment on those claims was thereafter entered pursuant to Federal Rule of Civil Procedure 54(b) on December 5, 2017. See J. (Doc. No. 146) (Palk, J.). The Court also dismissed Luna's and Willenbucher's claims against Trust I on January 18, 2019. See Order of Jan. 18, 2019 (Doc. No. 282) (Goodwin, J.). What remains are the individual claims of Lanier, Nibur, and Rath and the claims they have asserted on behalf of putative class members under section 10(b) and/or section 20(a) of the Exchange Act and under Rule 10b-5 against Defendants SandRidge, Ward, Bennett, Grubb, and Trust I.
Defendants originally argued in their Rule 12(c) motion that the Exchange Act claims brought by Lead Plaintiffs on behalf of the putative class members were time-barred. Based on Lead Plaintiffs' response, Defendants have now contended that all Exchange Act claims in this action are untimely. Thus, Defendants invoke their affirmative defense of the statute of limitations, contending that Plaintiffs' claims were asserted after expiration of the two-year limitations period set forth in 28 U.S.C. § 1658(b)(1) for Exchange Act claims.
Rule 12(c) permits a party to move for judgment on the pleadings "[a]fter the pleadings are closed—but early enough not to delay trial." Fed. R. Civ. P. 12(c). The Court evaluates the motion under the familiar standard for Federal Rule of Civil Procedure 12(b)(6) motions. See Atl. Richfield Co. v. Farm Credit Bank of Wichita, 226 F.3d 1138, 1160 (10th Cir. 2000) (citing Mock v. T.G. & Y. Stores Co., 971 F.2d 522, 528 (10th Cir. 1992)); see, e.g., Denver Health & Hosp. Auth. v. Beverage Distribs. Co., LLC, 546 F. App'x 742, 745 (10th Cir. 2013). Accordingly, the Court "accept[s] the well-pleaded allegations of the [operative] complaint as true and construe[s] them in the light most favorable to the non-moving party." Realmonte v. Reeves, 169 F.3d 1280, 1283 (10th Cir. 1999).
While the Court may dismiss a claim on the pleadings based on an affirmative defense
Section 1658(b)(1)'s two-year limitations period "begins to run upon discovery of the facts constituting the violation." China Agritech, Inc. v. Resh, 138 S.Ct. 1800, 1804 (2018). The term "discovery" as used in § 1658(b)(1) was interpreted by the Supreme Court in Merck & Co., Inc. v. Reynolds, 559 U.S. 633 (2010). Because the arguments in this case implicate principles explained in Merck, the Court recites the relevant discussion at length.
In Merck, a group of investors had brought suit on November 6, 2003, against Merck & Co., Inc. and others under section 10(b), alleging that these defendants had "knowingly misrepresented the risks of heart attacks accompanying the use of Merck's pain-killing drug, Vioxx (leading to economic losses when the risks later became apparent)." Merck, 559 U.S. at 637-38. The district court dismissed plaintiffs' complaint as untimely, concluding that certain pre-November 2001 events "should have alerted the plaintiffs to a possibility that Merck had knowingly misrepresented material facts no later than October 9, 2001, thus placing the plaintiffs on `inquiry notice' to look further." Id. at 643 (emphasis and internal quotation marks omitted);
In affirming the court of appeals' decision, the Supreme Court agreed "that Congress intended courts to interpret the word `discovery' in § 1658(b)(1)" as "encompass[ing] not only to those facts the plaintiff actually knew, but also those facts a reasonably diligent plaintiff would have known." Merck, 559 U.S. at 646, 648. Applying that interpretation, the Supreme Court rejected Merck's argument that § 1658(b)(1) did "not require `discovery' of scienter-related `facts.'" Id. at 648. It held: "The statute says that the limitations period does not begin to run until `discovery of the facts constituting the violation.' Scienter is assuredly a `fact.'"
Id. at 648-49 (alterations in original) (emphasis, citations, and internal quotation marks omitted).
The Supreme Court rejected Merck's next argument that, "even if `discovery' requires facts related to scienter, facts that tend to show a materially false or misleading statement (or material omission) are ordinarily sufficient to show scienter as well." Id. at 649. The Supreme Court "recognize[d] that certain statements are such that, to show them false is normally to show scienter as well," but found that in section 10(b) cases "the relation of factual falsity and state of mind is more context specific. An incorrect prediction about a firm's future earnings, by itself, does not automatically tell us whether the speaker deliberately lied or just made an innocent (and therefore nonactionable) error." Id. at 650. Accordingly, § 1658(b)(1) "may require `discovery' of scienter-related facts beyond the facts that show a statement (or omission) to be materially false or misleading." Id.
The Supreme Court also took issue with terminology used by Merck and in the courts below, including that the limitations period begins to run when plaintiffs are "on `inquiry notice'"—that is, "the point at which a plaintiff possesses a quantum of information sufficiently suggestive of wrongdoing that he should conduct a further inquiry." Id. (internal quotation marks omitted). Noting § 1658(b)(1)'s express language, the Supreme Court held that a plaintiff's claim does not accrue "when a plaintiff would have begun investigating" but upon "the `discovery' of" the "`facts constituting the violation.'" Id. at 651. It stated that "[i]f the term `inquiry notice' refers to the point where the facts would lead a reasonably diligent plaintiff to investigate further, that point is not necessarily the point at which the plaintiff would already have discovered facts showing scienter or other `facts constituting the violation.'" Id. And, similarly, the Supreme Court stated that events commonly characterized as "storm warnings" "may be useful to the extent that they identify a time when the facts would have prompted a reasonably diligent plaintiff to begin investigating." Id. at 653.
In evaluating the timeliness of the Exchange Act claims in this case, the Court, as the Supreme Court has cautioned, must be cognizant that § 1658(b)(1)'s two-year limitations period did not begin to run (and Lead Plaintiffs' Exchange Act claims did not accrue) until, as shown by the allegations in the pleadings, Lead Plaintiffs "did in fact discover, or . . . a reasonably diligent plaintiff would have discovered, `the facts constituting the violation,'"—"includ[ing] the fact of scienter"—"whichever [came] first." Id. at 637 (emphasis added) (quoting 28 U.S.C. § 1658(b)(1)). These "discovery principles cannot be evaded by [Lead Plaintiffs'] inaction." De Vito, 2018 WL 6891832, at *25. Rather, "they apply `irrespective of whether . . . [Lead] [P]laintiff[s] undertook a reasonably diligent investigation.'" Id. (quoting Pension Trust Fund for Operating Eng'rs v. Mortg. Asset Securitization Transactions, Inc., 730 F.3d 263, 275 (3d Cir. 2013)).
According to Defendants, because Lead Plaintiffs' "own dispositive admissions" show "without exception or qualification," that "all elements of Defendants' fraudulent conduct, including scienter, were revealed to the investing public, including Plaintiffs, by November 9, 2012," the Exchange Act claims filed more than two years later, on June 9, 2015, are time-barred. Defs.' Am. Reply (Doc. No. 242) at 2, 3 (emphasis omitted).
Lead Plaintiffs respond that they had not and could not have discovered by November 2012 (or any time more than two years prior to June 9, 2015) the facts related to scienter. They contend that their Exchange Act claims "did not begin to run any earlier than July 23, 2013," the day the first consolidated amended complaint was filed in SandRidge. Pls.' Mem. at 11 (emphasis omitted); see SandRidge Consol. Am. Compl. (Doc. No. 67).
Lead Plaintiffs note that in SandRidge, the Court on August 27, 2015, found that the allegations in support of the essential element of scienter in that case—allegations filed by "sophisticated institutional investors and their experienced securities class action counsel"—were deficient. See Pls.' Mem. at 6, 11. According to Lead Plaintiffs, because the Court "necessarily determined that the November 2012 disclosures did not reveal scienter," Defendants cannot now claim that those same November 2012 disclosures provided Lead Plaintiffs sufficient information to trigger the two-year time limit in § 1658(b)(1). Id. at 13.
In the August 27, 2015 Order, the Court considered whether the allegations in SandRidge met the PSLRA's "heightened pleading standard" and, specifically, "satisf[ied] the scienter requirement—a mental state embracing intent to deceive, manipulate, or defraud." SandRidge, Order of Aug. 27, 2015, at 24 (internal quotation marks omitted). The Court found that
Id. at 28-29 (ninth and eleventh alteration in original) (footnotes omitted); see also id. at 22.
Again, the question before the Court is when—as shown by the pleadings in this case—Lead Plaintiffs discovered, or a reasonably diligent plaintiff would have discovered, sufficient facts regarding Defendants' state of mind to start the two-year limitations period.
As to whether Defendants have shown that the pleadings establish facts that "would have prompted a reasonably diligent plaintiff to begin investigating" whether Defendants were at fault by November 2012, Merck, 559 U.S. at 653, the Court finds that a reasonably diligent plaintiff who had purchased Trust I Units and who had sustained damages when the price of those units declined might have determined that inquiry into the cause of that decline was warranted. "[E]vidence that Trust I's wells were not performing as well as expected began to emerge in late 2011." Consol. Am. Compl. (Doc. No. 78) ¶ 307. During Trust I conference calls in 2011 and 2012, analysts: "raised pointed questions," id.; inquired about certain "ominous signs of Trust I Wells' declining oil production," id. ¶ 294; and "expressed concern over the drop in oil production in the Mississippian Formation," id. ¶ 230. And, "the truth" was further "revealed" on November 8, 2012, when investor Singh publicly issued his letter complaining about "SandRidge's `disastrous performance.'" SandRidge Compl. at 24 (emphasis and capitalization omitted), ¶ 52; see also SandRidge, Corr. Consol. Am. Compl. (Doc. No. 75) ¶ 322. Such allegations alone, however, are not enough to establish as a matter of law when a reasonable plaintiff, diligently investigating these alleged "storm warnings," would have discovered the facts constituting the cause of action, including the fact that any named defendant acted either recklessly or with the intent to deceive, manipulate, or defraud Trust I Unitholders. See City of Pontiac Gen. Emps.' Ret. Sys. v. MBIA, Inc., 637 F.3d 169, 174 (2d Cir. 2011) (noting that absent actual knowledge, "the limitations period commences not when a reasonable investor would have begun investigating, but when such a reasonable investor conducting such a timely investigation would have uncovered the facts constituting a violation").
While a court may dismiss a claim on the pleadings based on an affirmative defense under Federal Rule of Civil Procedure 12(c), it is only appropriate to do so when a plaintiff's pleadings "admit[ ] all the elements of the affirmative defense by alleging the factual basis for those elements." Fernandez, 883 F.3d at 1299. Because application of a limitations period is most often a fact-intensive inquiry, see Merck, 559 U.S. at 652 (citing Young v. Lepone, 305 F.3d 1, 9 (1st Cir. 2002) ("[A] reasonably diligent investigation . . . may consume as little as a few days or as much as a few years to get to the bottom of the matter.")), and because Defendants have not shown at this stage of the proceeding that the allegations in Lead Plaintiffs' pleadings "make clear that the right sued upon [in this case] has been extinguished,'" Solomon, 395 F. App'x at 497 (internal quotation marks omitted), the Court DENIES Defendants' Motion for Partial Judgment on the Pleadings (Doc. No. 215). Such denial is without prejudice should discovery reveal a basis for again challenging the timeliness of Lead Plaintiffs' Exchange Act claims.
(1) 2 years after the discovery of the facts constituting the violation; or (2) 5 years after such violation.
Id. (internal quotation marks omitted).
Defendants SandRidge, Bennett, and Grubb raised the affirmative defense of statute of limitations in their answers to the consolidated amended complaint. See SandRidge's Answer (Doc. No. 137) ¶ 388; Bennett and Grubb's Answer (Doc. No. 138) at 79, ¶ 28. Ward and Trust I did not assert this affirmative defense in their responsive pleadings. See Ward's Answer (Doc. No. 140), at 16-20; Trust I's Answer (Doc. No. 141) at 45-48. Because Lead Plaintiffs have not complained that Ward's and Trust I's failure to do so has prejudiced them, the Court finds Ward and Trust I have not waived their right to assert this affirmative defense.
(a) a March 2000 study conducted by Merck that "compared Vioxx with another painkiller, naproxen" and showed that while "persons taking Vioxx suffered fewer gastrointestinal side effects," "approximately 4 out of every 1,000 participants who took Vioxx suffered heart attacks, compared to only 1 per 1,000 participants who took naproxen," Merck, 559 U.S. at 639;
(b) a Food and Drug Administration ("FDA") "warning letter released to the public on September 21, 2001," that read in part "that, in respect to cardiovascular risks, Merck's Vioxx marketing was `false, lacking in fair balance, or otherwise misleading,'" id. at 640 (internal quotation marks omitted); and
(c) Merck's response on October 9, 2001, as reported in the New York Times, to the FDA letter, the filing of "more products-liability lawsuits," and the drop in Merck's share price: "Merck ha[s] reexamined its own data and `[finds] no evidence that Vioxx increase[s] the risk of heart attacks,'" id. at 641 (internal quotation marks omitted).
Id. at 8-9 (citing Consol. Am. Comp. (Doc. No. 78) ¶¶ 68-73). The Court further found that the allegations regarding Defendants Ward and Grubb's "motive further support[ed] a finding . . . [of] scienter." Id. at 9 (citing Consol. Am. Compl. (Doc. No. 78) ¶¶ 299-304). As to Defendant Bennett, the Court found that the allegations in the consolidated amended complaint failed to sufficiently allege scienter and dismissed the section 10(b) claims against him. See id.